Regeneron Pharmaceuticals (REGN)

$558.87 +13.41 (2.46%)
Market Cap 58.89B
Revenue (ttm) 14.20B
Net Income (ttm) 4.41B
EPS (ttm) N/A
PE Ratio 14.53
Forward PE 19.69
Profit Margin 31.07%
Debt to Equity Ratio 0.07
Volume 1,656,700
Avg Vol 1,213,184
Day's Range N/A - N/A
Shares Out 107.97M
Stochastic %K 41%
Beta 0.33
Analysts Strong Sell
Price Target $737.83

Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to...

Industry: Biotechnology
Sector: Healthcare
Phone: 914 847 7000
Address:
777 Old Saw Mill River Road, Tarrytown, United States
c33k
c33k Aug. 2 at 12:50 AM
$REGN Crazy manipulation today. stock should be higher. unfairly punished for eyelea. also odronextamab CRL is due to Catalent issues not efficacy of the drug itself. its passed in EU.
1 · Reply
kinderspiel
kinderspiel Aug. 1 at 9:36 PM
$REGN Regeneron Pharmaceuticals Price $ 558.87 (+2.5%) Trade Count: 1,707 Total $ 4.6 M (90-Day Avg : 22.91 M) Call $ 2.6 M Put $ 2.0 M
0 · Reply
kenbkb
kenbkb Aug. 1 at 9:27 PM
$REGN DUPIXENT Schleifer discussed new indications and market expansion: "Over the past 10 months, three new indications chronic obstructive pulmonary disease or COPD, chronic spontaneous urticaria or CSU and bullous pemphigoid or BP were approved by the FDA, enabling Dupixent to potentially treat more than 600,000 additional biologic eligible patients."
0 · Reply
Yandthe
Yandthe Aug. 1 at 7:50 PM
$REGN why suddenly up ?
1 · Reply
EmbraceVolatility
EmbraceVolatility Aug. 1 at 7:43 PM
$REGN Bought 200 for $545 and sold the Aug 8th $550 call for $12. Already regret. Lol
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 1 at 7:36 PM
$REGN now it's moving to the upside, I'm sure they let them cover today on the open- a 40 point drop really?
0 · Reply
Yandthe
Yandthe Aug. 1 at 7:09 PM
$REGN can someone explain what happened here today because I can’t understand this crap
0 · Reply
Yandthe
Yandthe Aug. 1 at 7:01 PM
$REGN should’ve bought $LLY ..damn
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 1 at 6:06 PM
$REGN all the kooks are on here today... trying to get you to sell. This stock has everything going for it right now.
1 · Reply
kenbkb
kenbkb Aug. 1 at 5:50 PM
$REGN Odronextamab has already been approved in the EU under the brand name Ordspono for relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma after two or more lines of systemic therapy.
1 · Reply
Latest News on REGN
Regeneron: Rapidly Decreasing Importance Of Eylea

Aug 1, 2025, 4:05 PM EDT - 17 hours ago

Regeneron: Rapidly Decreasing Importance Of Eylea

Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 1:46 PM EDT - 20 hours ago

Regeneron Pharmaceuticals, Inc. (REGN) Q2 2025 Earnings Call Transcript

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

Aug 1, 2025, 12:01 PM EDT - 21 hours ago

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

ABBV AMGN AZN BMY GILD GSK JNJ

US FDA declines to approve Regeneron's blood cancer therapy for second time

Aug 1, 2025, 10:10 AM EDT - 23 hours ago

US FDA declines to approve Regeneron's blood cancer therapy for second time

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 1 day ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Regeneron beats second-quarter results estimates on Dupixent sales boost

Aug 1, 2025, 8:22 AM EDT - 1 day ago

Regeneron beats second-quarter results estimates on Dupixent sales boost

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 1 day ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Regeneron Reports Second Quarter 2025 Financial and Operating Results

Aug 1, 2025, 6:30 AM EDT - 1 day ago

Regeneron Reports Second Quarter 2025 Financial and Operating Results

Regeneron Pharmaceuticals Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Aug 1, 2025, 5:17 AM EDT - 1 day ago

Regeneron Pharmaceuticals Likely To Report Lower Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

Jul 31, 2025, 3:35 PM EDT - 1 day ago

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

ABBV AMGN AZN BMY GILD GSK JNJ

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

Jul 31, 2025, 3:00 PM EDT - 1 day ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

ABBV AMGN AZN BMY GILD GSK JNJ

Trump pressures 17 pharma CEOs to cut US drug prices

Jul 31, 2025, 2:28 PM EDT - 1 day ago

Trump pressures 17 pharma CEOs to cut US drug prices

ABBV AMGN AZN BMY GILD GSK JNJ

Trump posts letters to 17 pharmaceutical companies about drug prices

Jul 31, 2025, 2:19 PM EDT - 1 day ago

Trump posts letters to 17 pharmaceutical companies about drug prices

ABBV GILD LLY PFE AMGN AZN BMY

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

Jul 31, 2025, 1:48 PM EDT - 1 day ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

ABBV AMGN AZN BMY GILD GSK JNJ

5 Stocks That Launched New Dividends In This Roller-Coaster Market

Jul 29, 2025, 10:05 AM EDT - 3 days ago

5 Stocks That Launched New Dividends In This Roller-Coaster Market

MRP VTOL WDC WSC

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation

Jul 24, 2025, 7:30 AM EDT - 9 days ago

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation

Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025

Jul 10, 2025, 9:15 AM EDT - 23 days ago

Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025

Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment

Jul 2, 2025, 11:45 AM EDT - 4 weeks ago

Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment

US FDA approves Regeneron's blood cancer therapy

Jul 2, 2025, 11:11 AM EDT - 4 weeks ago

US FDA approves Regeneron's blood cancer therapy

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

Jun 26, 2025, 4:05 PM EDT - 5 weeks ago

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade

Jun 25, 2025, 9:19 AM EDT - 5 weeks ago

Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

Jun 24, 2025, 7:30 AM EDT - 5 weeks ago

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jun 23, 2025, 6:10 PM EDT - 5 weeks ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN GPCR LLY NVO PFE VKTX XBI

Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease

Jun 20, 2025, 2:01 AM EDT - 6 weeks ago

Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease

SNY

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Jun 20, 2025, 1:00 AM EDT - 6 weeks ago

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Jun 20, 2025, 1:00 AM EDT - 6 weeks ago

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

SNY

Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer

Jun 16, 2025, 5:23 PM EDT - 6 weeks ago

Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer

Former 23andMe CEO Anne Wojcicki wins bid for control of her former company, topping Regeneron

Jun 16, 2025, 7:06 AM EDT - 6 weeks ago

Former 23andMe CEO Anne Wojcicki wins bid for control of her former company, topping Regeneron

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Jun 15, 2025, 11:22 AM EDT - 6 weeks ago

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

SNY

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

Jun 15, 2025, 11:21 AM EDT - 6 weeks ago

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research

Jun 11, 2025, 9:00 AM EDT - 7 weeks ago

Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research

Regeneron Pharma Shares Rise Over 3% After Key Signal

Jun 10, 2025, 7:48 AM EDT - 7 weeks ago

Regeneron Pharma Shares Rise Over 3% After Key Signal

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript

Jun 9, 2025, 12:44 PM EDT - 7 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Jun 7, 2025, 6:30 PM EDT - 7 weeks ago

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Why Regeneron Is Falling And Why You Should Avoid It

Jun 4, 2025, 11:19 AM EDT - 2 months ago

Why Regeneron Is Falling And Why You Should Avoid It

REGN Stock Undervalued At $500?

Jun 2, 2025, 9:10 AM EDT - 2 months ago

REGN Stock Undervalued At $500?

Regeneron's weight-loss drug helps preserve muscle mass in study

Jun 2, 2025, 7:12 AM EDT - 2 months ago

Regeneron's weight-loss drug helps preserve muscle mass in study

Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist

Jun 2, 2025, 7:05 AM EDT - 2 months ago

Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

May 31, 2025, 8:04 AM EDT - 2 months ago

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet

May 30, 2025, 5:35 PM EDT - 2 months ago

S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet

ULTA

Regeneron dashes Wall Street's hopes as COPD treatment trial suffers a failure

May 30, 2025, 3:19 PM EDT - 2 months ago

Regeneron dashes Wall Street's hopes as COPD treatment trial suffers a failure

Itepekimab Failure A Setback For Sanofi And Regeneron

May 30, 2025, 2:10 PM EDT - 2 months ago

Itepekimab Failure A Setback For Sanofi And Regeneron

SNY

Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More

May 30, 2025, 12:30 PM EDT - 2 months ago

Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More

COO ULTA

Regeneron stock crashes on COPD data: here's why I'm buying REGN today

May 30, 2025, 12:04 PM EDT - 2 months ago

Regeneron stock crashes on COPD data: here's why I'm buying REGN today

Elastic, Gap, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session

May 30, 2025, 9:10 AM EDT - 2 months ago

Elastic, Gap, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session

ESTC GAP

Regeneron shares slide on mixed trial data on smoker's lung drug

May 30, 2025, 6:37 AM EDT - 2 months ago

Regeneron shares slide on mixed trial data on smoker's lung drug

Sanofi, Regeneron's Itepekimab Delivers Mixed Results in Late-Stage Trials

May 30, 2025, 3:19 AM EDT - 2 months ago

Sanofi, Regeneron's Itepekimab Delivers Mixed Results in Late-Stage Trials

SNY

Mary Kay Inc. Awards 10 Grants to Young Innovators at 2025 Regeneron International Science and Engineering Fair

May 28, 2025, 4:29 PM EDT - 2 months ago

Mary Kay Inc. Awards 10 Grants to Young Innovators at 2025 Regeneron International Science and Engineering Fair

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

May 28, 2025, 9:00 AM EDT - 2 months ago

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

May 22, 2025, 5:00 PM EDT - 2 months ago

Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

c33k
c33k Aug. 2 at 12:50 AM
$REGN Crazy manipulation today. stock should be higher. unfairly punished for eyelea. also odronextamab CRL is due to Catalent issues not efficacy of the drug itself. its passed in EU.
1 · Reply
kinderspiel
kinderspiel Aug. 1 at 9:36 PM
$REGN Regeneron Pharmaceuticals Price $ 558.87 (+2.5%) Trade Count: 1,707 Total $ 4.6 M (90-Day Avg : 22.91 M) Call $ 2.6 M Put $ 2.0 M
0 · Reply
kenbkb
kenbkb Aug. 1 at 9:27 PM
$REGN DUPIXENT Schleifer discussed new indications and market expansion: "Over the past 10 months, three new indications chronic obstructive pulmonary disease or COPD, chronic spontaneous urticaria or CSU and bullous pemphigoid or BP were approved by the FDA, enabling Dupixent to potentially treat more than 600,000 additional biologic eligible patients."
0 · Reply
Yandthe
Yandthe Aug. 1 at 7:50 PM
$REGN why suddenly up ?
1 · Reply
EmbraceVolatility
EmbraceVolatility Aug. 1 at 7:43 PM
$REGN Bought 200 for $545 and sold the Aug 8th $550 call for $12. Already regret. Lol
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 1 at 7:36 PM
$REGN now it's moving to the upside, I'm sure they let them cover today on the open- a 40 point drop really?
0 · Reply
Yandthe
Yandthe Aug. 1 at 7:09 PM
$REGN can someone explain what happened here today because I can’t understand this crap
0 · Reply
Yandthe
Yandthe Aug. 1 at 7:01 PM
$REGN should’ve bought $LLY ..damn
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 1 at 6:06 PM
$REGN all the kooks are on here today... trying to get you to sell. This stock has everything going for it right now.
1 · Reply
kenbkb
kenbkb Aug. 1 at 5:50 PM
$REGN Odronextamab has already been approved in the EU under the brand name Ordspono for relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma after two or more lines of systemic therapy.
1 · Reply
kenbkb
kenbkb Aug. 1 at 5:49 PM
$REGN This has a good chance of being [resolved] expeditiously," said CEO Leonard Schleifer on the company's second-quarter earnings call Friday morning. "These were not structural changes that are being requested by the FDA. It's not like they have to rebuild something… They're mainly process [and] procedural, those sorts of things." "We are expecting — once the resolution of the filling issues has occurred — to receive favourable action, we hope, from the FDA," he added.
0 · Reply
Yandthe
Yandthe Aug. 1 at 5:46 PM
$REGN sold with 20k loss .. i hate this stock
0 · Reply
kenbkb
kenbkb Aug. 1 at 5:46 PM
$REGN Regeneron said Novo has been in communication with the FDA and expects to submit its response next week. The company said it expects an expeditious resolution of the filling issues for Eylea HD, citing its review of the FDA's observations and Novo's proposed response, along with progress it has made with alternate third-party fillers.
0 · Reply
Yandthe
Yandthe Aug. 1 at 5:34 PM
$REGN so depressed on what happened today .. this looks like will never see 600 again
0 · Reply
Yandthe
Yandthe Aug. 1 at 5:31 PM
$REGN 620 avg should.. should i sell ?
1 · Reply
Hshebeeishb
Hshebeeishb Aug. 1 at 5:14 PM
$REGN see you next week at 450 .. stay safe and GLTA
0 · Reply
Hshebeeishb
Hshebeeishb Aug. 1 at 5:05 PM
$REGN buy 545 sell at 550 .. penny stock action
0 · Reply
Hshebeeishb
Hshebeeishb Aug. 1 at 5:02 PM
$REGN we have no buyers here ,, only sellers
0 · Reply
Hshebeeishb
Hshebeeishb Aug. 1 at 5:01 PM
$REGN fake pumper
0 · Reply
AlanVert351
AlanVert351 Aug. 1 at 4:47 PM
$REGN WKSP this is it. no more waiting. no more “watching.” float’s vanishing. volume twitchin. filings been silent for too long. you either buy now or spend the next 3 months coping in the replies. i’m not missing this one. 🚀💥
0 · Reply
Hshebeeishb
Hshebeeishb Aug. 1 at 4:44 PM
$REGN institutional investors are unloading 😂
0 · Reply
bullish51892
bullish51892 Aug. 1 at 4:35 PM
$REGN Waiting for confirmation to buy in, but this is obviously an amazing deal and under any other administration it would be up 15-20% today. Percentage wise, even stronger earnings beat than $META 😳😳💰💰
1 · Reply